MRSA: Antibiotic, Baxdela launched in the US
by Robert Herriman from Outbreak News Today on (#3EK05)
Melinta Therapeutics, Inc. , a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced the U.S. launch of intravenous and oral formulations of Baxdelaa (delafloxacin) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. With Baxdela, no dosage adjustments are ["]
The post MRSA: Antibiotic, Baxdela launched in the US appeared first on Outbreak News Today.